

SLC12A1 Antibody (N-term) Blocking peptide

Synthetic peptide Catalog # BP12325a

Specification

SLC12A1 Antibody (N-term) Blocking peptide - Product Information

Primary Accession

013621

SLC12A1 Antibody (N-term) Blocking peptide - Additional Information

Gene ID 6557

Other Names

Solute carrier family 12 member 1, Bumetanide-sensitive sodium-(potassium)-chloride cotransporter 2, Kidney-specific Na-K-Cl symporter, SLC12A1, NKCC2

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

SLC12A1 Antibody (N-term) Blocking peptide - Protein Information

Name SLC12A1

Synonyms NKCC2 {ECO:0000303|PubMed:8640224}

Function

Renal sodium, potassium and chloride ion cotransporter that mediates the transepithelial NaCl reabsorption in the thick ascending limb and plays an essential role in the urinary concentration and volume regulation (PubMed:21321328). Electrically silent transporter system (By similarity).

Cellular Location

Apical cell membrane; Multi-pass membrane protein

Tissue Location

Kidney; localizes to the thick ascending limbs (at protein level).

SLC12A1 Antibody (N-term) Blocking peptide - Protocols



Provided below are standard protocols that you may find useful for product applications.

• Blocking Peptides

SLC12A1 Antibody (N-term) Blocking peptide - Images

SLC12A1 Antibody (N-term) Blocking peptide - Background

This gene encodes a kidney-specificsodium-potassium-chloride cotransporter that is expressed on theluminal membrane of renal epithelial cells of the thick ascendinglimb of Henle's loop and the macula densa. It plays a key role inconcentrating urine and accounts for most of the NaCl resorption. It is sensitive to such diuretics as furosemide and bumetanide. Some Bartter-like syndromes result from defects in this gene. Alternative splicing results in multiple transcript variantsencoding distinct isoforms. Additional splice variants have been described but their biological validity in humans has not been experimentally proven.

SLC12A1 Antibody (N-term) Blocking peptide - References

Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010)Carota, I., et al. Acta Physiol (Oxf) 199(3):327-338(2010)Bralten, L.B., et al. Genes Chromosomes Cancer 49(6):509-517(2010)Yokoyama, K., et al. Nephron Clin Pract 115 (4), C237-C243 (2010) :Castrop, H., et al. Am. J. Physiol. Renal Physiol. 295 (4), F859-F866 (2008) :